Kane Biotech Inc.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company focused on the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms. With over 20 years of experience, the company aims to create smarter ways to fight bacteria, holding 50 patents and patents pending in biotechnology, primarily targeting biofilms.

Products & Services

revyve™ Antimicrobial Wound Gel:A wound gel combining Kane's patented coactiv+™ technology in a thermo-reversible gel, providing a moist environment for wound healing. It transforms from liquid to gel with temperature, is easy to apply and rinse off, and fits within US reimbursement limits.

DermaKB™ Scalp Care Products:A line of scalp detoxifiers and shampoos designed to break down biofilms, addressing common scalp conditions like dandruff and seborrheic dermatitis. Sold directly to consumers via Amazon and Kane's online store, with positive results from a large-scale consumer trial.

Kane Wound Care & Surgical:A division focused on wound care and surgical solutions targeting biofilms, operating in a global market expected to reach US $22 billion by 2022.

Kane Dermatology:A subsidiary developing non-prescription consumables for minor health ailments related to biofilms, sold directly to end customers.

Specialties

Biofilm prevention and removal Wound care Dermatology Antimicrobial technologies Research and development in biotechnology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 700000 MR: - FA: $700,000 FAN: 700000	D: 2025-12-18 FD: 2025-12-18	1 investors
2	RT: Private Placement T: - FT: Private Placement	A: 800000 MR: - FA: up to $800,000 FAN: 800000	D: 2025-11-27 FD: 2025-11-27	1 investors
3	RT: Convertible Debenture T: - FT: Convertible Debenture	A: 1000000 MR: - FA: $1 million FAN: 1000000	D: 2025-06-26 FD: 2025-06-26	1 investors
4	RT: Private Placement T: - FT: Private Placement	A: 1200000 MR: - FA: $1,200,000 FAN: 1200000	D: 2025-05-05 FD: 2025-05-05	1 investors
5	RT: Private Placement T: - FT: Private Placement	A: 1275000 MR: - FA: $1,275,000 FAN: 1275000	D: 2025-01-20 FD: 2025-01-20	1 investors
6	RT: Non-brokered private placement T: - FT: Non-brokered private placement	A: 3000000 MR: - FA: 3,000,000 FAN: 3000000	D: 2024-12-03 FD: 2024-12-03	-
7	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 500000 MR: - FA: 500,000 FAN: 500000	D: 2024-09-12 FD: 2024-09-12	1 investors
8	RT: Grant T: - FT: Grant	A: 200000 MR: - FA: up to $200,000 FAN: 200000	D: 2024-08-13 FD: 2024-08-13	1 investors
9	RT: Private Placement T: - FT: Private Placement	A: 500000 MR: - FA: up to $500,000 FAN: 500000	D: 2023-08-03 FD: 2023-08-03	1 investors
10	RT: Debt T: - FT: Debt	A: 1000000 MR: - FA: $1,000,000 FAN: 1000000	D: 2023-03-02 FD: 2023-03-02	1 investors

Private Placement Latest

2025-12-18

$700K

1 investor (Pro only)

Private Placement 2025-11-27

$800K

Convertible Debenture 2025-06-26

$1.0M

View 9 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Robert Huizinga

Interim Chief Executive Officer

R

Ray Dupuis

Chief Financial Officer

L

Lori Christofalos

Chief Quality Officer

P

Philip Renaud

Board Chair

J

John Coleman

Director

A

Anne Greven

Director

View 5 more team members with Pro

Unlock Full Team Directory

Recent News

Kane Biotech Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised